Localized scleroderma
Drug research and approvals for localized scleroderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 5 studies of localized scleroderma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 5
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 5 recruiting on ClinicalTrials.gov ↗- Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed…NCT07292961 · Not applicable · Hacettepe University · starts Dec 4, 2025
- Patients Diagnosed With Scleroderma and Their Chewing and Swallowing PerformanceNCT07182981 · Not reported · Hacettepe University · starts Aug 4, 2025
- Patients Diagnosed With Scleroderma: Physical Performance and FunctionalityNCT07183072 · Not reported · Hacettepe University · starts Aug 4, 2025
- Connective Tissue Diseases and Lung ManifestationsNCT04095351 · Not reported · Medical University Innsbruck · starts Dec 9, 2019
- Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA RepositoryNCT01808937 · Not reported · University of Texas Southwestern Medical Center · starts May 1, 2007
Drug Pipeline
4 in phase 3, 8 in phase 2, 10 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Imiquimod
- Phase 3 Toll-like receptor 7 agonist
- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Cyclophosphamide anhydrous
- Phase 3 DNA inhibitor
- Nitroglycerin
- Phase 3 Soluble guanylate cyclase activator
- Riociguat
- Phase 2 Soluble guanylate cyclase positive allosteric modulator
- Lidocaine
- Phase 2 Sodium channel alpha subunit blocker
- Sildenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Imatinib
- Phase 2 Tyrosine-protein kinase ABL inhibitor
- Atorvastatin
- Phase 2 HMG-CoA reductase inhibitor
- Dupilumab
- Phase 2 Interleukin-4 receptor subunit alpha antagonist
- Crisaborole
- Phase 2 Phosphodiesterase 4 inhibitor
- BMS-986020
- Phase 2 Lysophosphatidic acid receptor Edg-2 antagonist
- Valproic acid
- Phase 1 Succinate semialdehyde dehydrogenase inhibitor
- Fludarabine
- Phase 1
- Tacrolimus anhydrous
- Phase 1 FK506-binding protein 1A inhibitor
- Sarilumab
- Phase 1 Interleukin-6 receptor alpha subunit antagonist
- Dasatinib anhydrous
- Phase 1 Tyrosine-protein kinase ABL inhibitor
- Calcipotriene
- Phase 1 Vitamin D receptor agonist
- Inebilizumab
- Phase 1 B-lymphocyte antigen CD19 binding agent
- Anifrolumab
- Phase 1 Interferon-alpha/beta receptor alpha chain antagonist
- Veledimex
- Phase 1
- Clobetasol
- Phase 1
How Its Trials Ended
130 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 38 whose ending is known, 37% met their primary endpoint, 18% missed it and 45% stopped early.
- Completed, result not reported5542%
- Ongoing2721%
- Met its primary endpoint1411%
- Status unknown108%
- Stopped: other or unclear97%
- Missed its primary endpoint75%
- Stopped: enrollment or feasibility54%
- Stopped: lack of efficacy11%
- Stopped: safety11%
- Stopped: sponsor or business decision11%
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Apr 26, 2006 | Peptide 144 TGF beta-1-inhibitorTreatment of localized scleroderma | Digna Biotech, S.L. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA